प्राथमिक स्रोत रिकॉर्ड
महत्वपूर्णअन्य
NRXP: FDA ने कीटामाइन ANDA में एक प्रमुख कमी (major deficiency) पाई
FDA completed first-round review of NRXP’s preservative-free ketamine ANDA with no drug-related deficiencies. One major deficiency was cited for the luer-lock vial tip; FDA requested manufacturer certifications that the vial is identical to three already-approved ANDAs. FDA committed to immediate re-review and shortest possible cycle.
मुख्य तथ्य
स्रोत का अंश
nrxp20260806_8k.htm false 0001719406 0001719406 2026-08-07 2026-08-07 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2026 NRX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38302 82-2844431 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification Number) 1201 Orange Street, Suite 600 Wilmington , Delaware 19801 (Address of principal executive offices) (Zip Code) ( 484 ) 254-6134 (Registrant ’ s telephone number, including area code) Not applicable (Former name or former address, if changed sinc
इस संपत्ति पर और
महत्वपूर्ण
17 अग॰ 2026
12:00 pm
NRXPNRX Pharmaceuticalsउल्लेखनीय
7 अग॰ 2026
08:01 pm
NRXPNRX PharmaceuticalsNRx Pharmaceuticals FDA ANDA समीक्षा कॉल 10 अगस्त को आयोजित करेगी
महत्वपूर्ण
17 फ़र॰ 2026
02:21 pm
NRXPNRX Pharmaceuticalsउल्लेखनीय
26 सित॰ 2025
12:01 pm
NRXPNRX PharmaceuticalsNRXP: FDA ने प्रिज़र्वेटिव-मुक्त कीटामाइन KETAFREE™ के लिए Suitability Petition को मंज़ूरी दी